Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (3)

Trial Status

Recruiting3

Clinical Trials (3)

Showing 3 of 3 trials
NCT06544265Phase 1Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

NCT05758610Phase 1RecruitingPrimary

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

NCT05186012Phase 1RecruitingPrimary

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Showing all 3 trials

Research Network

Activity Timeline